04 Jan SPL Medical – Next major clinical development milestone
SPL Medical announces fast achievement of next major clinical development milestone for its breakthrough platform product Ferrotran®: 100 patients included in Phase III trial...
Author: sysad
14 Dez SPL Medical announces achievement of major Phase III clinical development milestone
SPL medical has its proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached a major milestone by inclusion of more than 50 % of the planned patient group into this trial....
01 Nov New publication in European Urology Focus on the applicability of Ferrotran® (Ferumoxtran)
Patients with renal impairment cannot undergo angiography because iodine and gadolinium contrast agents are contraindicated. Iron-containing ultrasmall superparamagnetic iron oxide particles, such as ferumoxtran-10, are not contraindicated in these patients. Thus, patients with renal failure can still undergo angiography with ferumoxtran-10....
28 Sep SPL Medical announces collaboration with NanoEcho for application of Ferrotran® (Ferumoxtran)
SPL medical and NanoEcho have signed a Letter of Intent and initiated a cooperation on regulatory partnership and supply for SPL medical proprietary iron-based nanoparticle Ferrotran® (Ferumoxtran) product and platform....
07 Jul SPL Medical is pointing out a powerful publication in Investigative Radiology
SPL Medical is pointing out a powerful publication in Investigative Radiology elaborating a new reading algorithm for nano-MRI with Ferrotran® (Ferumoxtran) for the detection of even very small lymph nodes in head & neck cancer patients....
23 Mrz SPL Medical is pointing out a powerful publication in European Urology Focus
SPL Medical is pointing out a powerful publication in European Urology Focus highlighting the useability of Ferrotran® (Ferumoxtran) for MR-Angiography (MRA) even in renally impaired patients thus providing access to another market of approx. 1.5 bln USD with high growth rates....
25 Nov Ferumoxtran – zuverlässiger Helfer bei der Diagnostik des Lymphknotenbefalls (German only)
Der Befall der Lymphknoten ist bei Prostatakrebs ein entscheidender Faktor für die weitere Therapie. Bislang wird in der Diagnostik anhand der Größe der Lymphknoten abgeschätzt, ob diese von Krebszellen befallen sind; überschreiten Lymphknoten eine bestimmte Größe, so wird von einem Tumorbefall ausgegangen....
25 Nov Prostatakrebs: Bildgebung vor Biopsie! (German only)
Das Screening zur Früherkennung von Prostatakrebs ist ein kniffliger Balanceakt: Einerseits sollen möglichst alle relevanten Tumoren erkannt werden, andererseits können zu gründliche Verfahren zur Entdeckung ungefährlicher Befunde und Übertherapie samt Nebenwirkungen führen....
07 Okt SPL Medical announces long-term distribution agreement partnership for its novel contrast agent Ferrotran® (Ferumoxtran) for the Korean market
SPL Medical announced today that it has entered into an agreement for the distribution of its novel contrast agent Ferrotran® for the Korean market with Encormac Corp....
27 Mai SPL Medical announces the first time mentioning of its novel contrast agent Ferrotran® (Ferumoxtran) in the German S3-guidelines for Prostate Cancer
SPL Medical announced today that the new issue of the German S3-guidelines for prostate cancer, released this month by the Guideline Program Oncology of the German Cancer Society, Deutsche Krebshilfe and AWMF, for the first time is mentioning Ferrotran® (Ferumoxtran) on page 25 of the...